Nicola Thompson, Amphista Therapeutics CEO
May 4, 2022 08:55 AM EDTUpdated 10:51 AM
Deals
Pharma

An up­start pro­tein degra­da­tion con­tender adds Mer­ck KGaA and Bris­tol My­ers to its list of Big Phar­ma back­ers

Tyler Patchen

News Reporter

Am­phista Ther­a­peu­tics may not be the best-known name in the pro­tein degra­da­tion wing of biotech, but it has some mar­quee phar­ma names back­ing its work …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times